December 26, 2001
Premarket Notification

KO20122

FEB 1 5 2002

Section 16

Summary of Safety and Effectiveness

December 26, 2001 Premarket Notification

Summary of Safety and Effectiveness

This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and CFR 807.92.

1. Submitter's name, address, telephone number, contact person, and data summary prepared:

a. Millennium Biomedical Inc.

360 East Bonita Avenue

Pomona, California 91767

Phone:

(909)-621-7646

Fax:

(909)-621-7556

b. Contact Person:

Jerry Kaeni

President

c. Date Summary Prepared:

December 26, 2001

2. Name of device, including trade name and classification name:

a. Trade/Proprietary Name:

MB 102 Millennium Blades

b. Classification Name:

Keratome, AC-Powered, and/or Blades

3. Identification of the predicate device or legally marketed device or devices to which substantial equivalence is being claimed:

Company

Device

510(k) No.

Date Cleared

Chiron Vision

(Bausch & Lomb)

Microkeratome
which uses Bausch
& Lomb Accuglide™
blades

4. A description of the device that is the subject of the 510(k), including explanation of how device function, basic scientific concepts, significant physical and performance characteristics (design, material, physical properties):

The MB 102 Millennium Blade is a <u>replacement blade</u> designed to be used with the HansatomeTM Microkeratome. The MB 102 Millennium Blade is a single-use only, disposable device. The blade material is similar to that used in predicate devices (stainless steel).

5. A statement of intended use:

The MB 102 Millennium blade is intended to be used as a replacement blade for the HansatomeTM Microkeratome.

Millennium Biomedical Inc. MB 102 Millennium Blades

December 26, 2001 Premarket Notification

A statement of how the technological characteristics of the device compare to those of the predicate or legally marketed devices: 9

SUMMARY OF TECHNOLOGICAL CHARACTERISTICS OF DEVICE

MBI MB 102 MILLENNIUM BLADE	Indicated for use as a replacement blade for the Hansatome TM Microkeratome.	The blade is held in the keratome head and oscillates by means of the turbine. The keratome head adapts to the turbine by means of a threaded part. The turbine motor is gas powered.	Single edge blade with the plastic blade holder	52 Rockwell C Cobalt 60 radiation	Stainless steel	Delrin	Blade cutting edge
B&L Accuglide TM Blade (PREDICATE DEVICE)	Indicated for use with the Hansatome TM Microkeratome by surgeons to cut cornea in the form of a hinged flap in LASIK refractive surgery procedures.	The blade is held in the keratome head and oscillates by means of the turbine. The keratome head adapts to the turbine by means of a threaded part. The turbine motor is gas powered.	Single edge blade with the plastic blade holder	52 Rockwell C Cobalt 60 radiation	Stainless steel	Delrin	Blade cutting edge
CHARACTERISTICS	Intended Use	Operating Principle	Blade Design	Blade Hardness Sterilization Method	Blade Material	Blade Holder Material	Patient Contact Portion of Device

7. Brief summary of clinical tests and results

The performance of the MB 102 Millennium Blades was found to be acceptable the test results of the functional performance testing. The results showed that the functional performance of the MB 102 Millennium Blades was substantially equivalent to that of the predicate blade.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

FEB 1 5 2002

Mr. Jerry Kaeni President Millennium Biomedical Inc. 360 East Bonita Avenue Pomona, CA 91767

Re: K020122

Trade/Device Name: MB 102 Millennium Blade

Regulation Number: 21 CFR 886.4370

Regulation Name: Keratome

Regulatory Class: I Product Code: HNO

Dated: December 26, 2001 Received: January 14, 2001

Dear Mr. Kaeni:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

A. Ralph Rosenthal, M.D.

Director

Division of Ophthalmic and Ear,

Nose and Throat Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Device Name:	MB 102 Millennium Blade
ndications for Use:	
Γhe MB 102 Millenni Chiron Hansatome™	um blade is intended to be used as a replacement blade for the Microkeratome.
	WRITE BELOW THIS LINE-CONTINUE ON ANOTHER
PAGE IF NEEDED)	
PAGE IF NEEDED)	
PAGE IF NEEDED)	
PAGE IF NEEDED)	rence of CDRH, Office of Device Evaluation (ODE) Division Sign-Off) Division of Ophthalmic Ear,
PAGE IF NEEDED)	rence of CDRH, Office of Device Evaluation (ODE) Denis L. Carthy (Division Sign-Off) Division of Ophthalmic Ear, Nose and Throat Devises 510(k) Number KO20122